Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 435

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 435
---
 (the June 2025 Private Placement is reflected within Pro Forma AdjustmentCin Note 4 of the notes to the unaudited pro forma condensed combined financial information).As noted above, in addition to the shares of TuHURA Common Stock issued to the Purchasers who invested in the June 2025 Private Placement, an equal number of warrants to purchase the same amount of common shares at an exercise price of $3.3125 per warrant share were issued together with the common shares issued in the June 2025 Private Placement. These Warrants represent freestanding financial instruments issued together with the common stock purchased, however, they were determined to not be precluded from being classified as equity. As such, the shares underlying the Warrants are initially measured at their relative fair values and not remeasured for subsequent changes in fair value to be recognized as long as the Warrants continue to be classified in equity. Given that the Warrants were issued along with the common stock issued to the private investors in the June 2025 Private Placement and all the net proceeds are already reflected in the unaudited pro forma condensed combined balance sheet as of March 31, 2025 with the corresponding amount also recorded within equity (see Pro Forma AdjustmentCin Note 4 of the notes to the unaudited pro forma condensed combined financial information), the relative fair value that is allocated to the Warrants would also be reflected in that corresponding amount recorded within Additionalpaid-incapital. As a result, the accounting for the Warrants is determined to have zero net effect within equity outside of what is already reflected in Pro Forma Pro Forma AdjustmentC.F-176
UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF MARCH 31, 2025

| ASSETS                                    
 Current assets:                           |     | TuHURA            
 Biosciences, Inc. |            |     | Kineta       
 (Historical) |            |     | Additional 
 Financings |            |   |     |   |     | Pro Forma   
 Adjustments |             |   |     |    |     | Pro Forma 
 Combined  |            |
|:------------------------------------------|:----|:------------------|-----------:|:----|:-------------|-----------:|:----|:-----------|-----------:|:--|:----|:--|:----|:------------|------------:|:--|:----|:---|:----|:----------|